Ontario Teachers Pension Plan Board Sells 9,062 Shares of Amgen, Inc. (NASDAQ:AMGN)

Ontario Teachers Pension Plan Board reduced its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 64.4% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,003 shares of the medical research company’s stock after selling 9,062 shares during the quarter. Ontario Teachers Pension Plan Board’s holdings in Amgen were worth $1,014,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in the business. Citizens Financial Group Inc RI raised its holdings in Amgen by 25.0% during the 1st quarter. Citizens Financial Group Inc RI now owns 79,159 shares of the medical research company’s stock worth $16,048,000 after purchasing an additional 15,852 shares during the last quarter. Clear Harbor Asset Management LLC increased its stake in shares of Amgen by 0.9% in the 1st quarter. Clear Harbor Asset Management LLC now owns 6,445 shares of the medical research company’s stock valued at $1,307,000 after acquiring an additional 60 shares during the last quarter. Albion Financial Group UT increased its stake in shares of Amgen by 3.7% in the 1st quarter. Albion Financial Group UT now owns 20,206 shares of the medical research company’s stock valued at $4,096,000 after acquiring an additional 729 shares during the last quarter. Renaissance Investment Group LLC increased its stake in shares of Amgen by 2.9% in the 1st quarter. Renaissance Investment Group LLC now owns 2,547 shares of the medical research company’s stock valued at $516,000 after acquiring an additional 71 shares during the last quarter. Finally, Edge Capital Group LLC increased its stake in shares of Amgen by 37.6% in the 1st quarter. Edge Capital Group LLC now owns 30,168 shares of the medical research company’s stock valued at $6,116,000 after acquiring an additional 8,240 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages have recently commented on AMGN. Robert W. Baird cut Amgen from a “neutral” rating to an “underperform” rating and upped their price target for the company from $173.00 to $185.00 in a research note on Friday, January 31st. Guggenheim started coverage on Amgen in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $225.00 price target for the company. Morgan Stanley increased their target price on Amgen from $267.00 to $280.00 and gave the stock an “overweight” rating in a research note on Friday, May 1st. Bank of America increased their target price on Amgen from $250.00 to $265.00 and gave the stock a “buy” rating in a research note on Friday, May 1st. Finally, Mizuho reissued a “hold” rating and set a $215.00 target price on shares of Amgen in a research note on Thursday, April 30th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and seventeen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $244.65.

NASDAQ:AMGN opened at $226.43 on Friday. Amgen, Inc. has a twelve month low of $166.68 and a twelve month high of $244.99. The company has a quick ratio of 1.28, a current ratio of 1.59 and a debt-to-equity ratio of 3.16. The business has a 50 day moving average price of $228.36 and a two-hundred day moving average price of $225.14. The company has a market cap of $132.23 billion, a P/E ratio of 14.56, a price-to-earnings-growth ratio of 1.92 and a beta of 0.97.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.17 earnings per share for the quarter, topping analysts’ consensus estimates of $3.70 by $0.47. The firm had revenue of $6.16 billion during the quarter, compared to the consensus estimate of $6.01 billion. Amgen had a return on equity of 90.75% and a net margin of 32.03%. The business’s revenue was up 10.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.56 EPS. As a group, analysts anticipate that Amgen, Inc. will post 15.58 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 8th. Stockholders of record on Monday, May 18th will be issued a $1.60 dividend. This represents a $6.40 annualized dividend and a dividend yield of 2.83%. The ex-dividend date is Friday, May 15th. Amgen’s payout ratio is presently 43.18%.

In other news, Director Ronald D. Sugar sold 1,000 shares of the stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $233.35, for a total value of $233,350.00. Following the completion of the sale, the director now owns 15,636 shares of the company’s stock, valued at approximately $3,648,660.60. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director R Sanders Williams sold 425 shares of the stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $237.31, for a total value of $100,856.75. Following the completion of the sale, the director now directly owns 5,834 shares of the company’s stock, valued at approximately $1,384,466.54. The disclosure for this sale can be found here. In the last three months, insiders sold 2,425 shares of company stock valued at $563,477. 0.25% of the stock is currently owned by insiders.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Featured Article: Why is the conference call important?

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.